The Interplay of Chronic Hepatitis C and COVID-19: Implications for Prognosis and Treatment.

chronic hepatitis c (chc) covid-19 mortality sars-cov2 severe disease

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Aug 2024
Historique:
accepted: 11 08 2024
medline: 11 9 2024
pubmed: 11 9 2024
entrez: 11 9 2024
Statut: epublish

Résumé

Introduction Chronic hepatitis C (CHC) remains a significant public health concern due to both hepatic and extrahepatic manifestations associated with substantial morbidity and mortality. The emergence of SARS-CoV-2 has raised concerns about the outcomes of COVID-19 in CHC patients. Method We conducted a retrospective analysis of patients with CHC and SARS-CoV-2 infection admitted to a tertiary care hospital between 2020 and 2023. We performed a global analysis of the entire batch of patients and, later, we evaluated the patients according to the severity of the SARS-CoV-2 infection Results The cohort included 89 patients (63 females, 26 males) with a median age of 65 years. Most patients were hospitalized in 2021. Common clinical manifestations included fever, cough, digestive symptoms, and headache. The most frequent comorbidities were renal disease, thyroid disorders, and cancer. Univariate logistic regression analysis identified older age, hospitalization in 2021, and respiratory failure as risk factors for severe COVID-19. Elevated lactate dehydrogenase levels were also associated with an increased risk of severe COVID-19. Regarding CHC, detectable hepatitis C virus viremia was associated with more severe liver disease (p<0.01). Conclusion Patients with CHC and SARS-CoV-2 infection have a substantial risk of severe outcomes. Early identification and management of these patients are crucial to improve their prognosis.

Identifiants

pubmed: 39258096
doi: 10.7759/cureus.66639
pmc: PMC11386413
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e66639

Informations de copyright

Copyright © 2024, Lazar et al.

Déclaration de conflit d'intérêts

Human subjects: Consent was obtained or waived by all participants in this study. Institutuional Review Board of ”Dr. Victor Babeș” Hospital issued approval 19909. The current study protocol recived the ethical approval of the Institutuional Review Board of ”Dr. Victor Babeș” Hospital with the approval number 19909 from 28th of December 2020. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Stefan D Lazar (SD)

Infectious Diseases and Tropical Medicine, Dr Victor Babes Hospital of Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Andreea F Stoenescu (AF)

Infectious Diseases and Tropical Medicine, Dr Victor Babes Hospital of Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Corneliu Petru Popescu (CP)

Infectious Diseases and Tropical Medicine, Dr Victor Babes Hospital of Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Simin Florescu (S)

Infectious Diseases and Tropical Medicine, Dr Victor Babes Hospital of Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Geta Vancea (G)

Infectious Diseases and Tropical Medicine, Dr Victor Babes Hospital of Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Petre Calistru (P)

Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Classifications MeSH